Clinical Trials Directory

Trials / Completed

CompletedNCT00369694

Short Course Terlipressin for Control of Acute Variceal Bleeding

Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
130 (actual)
Sponsor
Aga Khan University · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether 24 hours of Terlipressin is as effective as 72 hours of Terlipressin in preventing re-bleed once esophageal variceal bleed has been controlled with endoscopic therapy (variceal band ligation or sclerotherapy) in low to moderate risk variceal bleed patients and hence can save cost and may decrease length of hospital stay especially in the I.C.U or high dependency units.

Detailed description

The esophageal variceal bleeding is usually controlled with endoscopic treatment of variceal band ligation or sclerotherapy along with vasoactive drugs like Terlipressin or Octreotide. The risk of re-bleeding is highest during the initial 5 days from first presentation. Terlipressin is usually given for 3 days (72 hours). In this study we are trying to prove that among low to moderate risk patients, a short course of 1 day (24 hours) of Terlipressin is as effective as 3 days (72 hours) in preventing re-bleed once bleeding has been controlled with endoscopic therapy. This intervention will save 2 days cost incurred on the Terlipressin and may also help in decreasing the length of hospital stay in future.

Conditions

Interventions

TypeNameDescription
DRUGTerlipressin2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
DRUGTerlipressin & then Dummy2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.

Timeline

Start date
2006-08-01
Primary completion
2008-07-01
Completion
2008-08-01
First posted
2006-08-29
Last updated
2008-09-25

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT00369694. Inclusion in this directory is not an endorsement.